A Phase 2b Study of BNC210 Tablet Formulation in Adults With Post-Traumatic Stress Disorder (PTSD)
Status:
Recruiting
Trial end date:
2023-05-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to assess the effects of BNC210 compared to placebo on PTSD
symptom severity as measured by CAPS-5 Total Symptom Severity Scores.